Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$3.23
+15.8%
$2.30
$1.03
$3.35
$647.09M1.442.19 million shs14.88 million shs
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$5.99
+3.5%
$4.82
$1.58
$6.44
$533.13M0.891.38 million shs5.07 million shs
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
$6.21
-3.7%
$6.18
$7.50
$19.22
$83.39M0.0174,040 shs14,775 shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$11.84
-5.5%
$10.67
$8.46
$26.50
$307.30M0.3697,508 shs61,404 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
+15.77%+23.28%+38.63%+119.73%+101.88%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+3.45%+13.02%+15.86%+93.23%+254.44%
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
+7.32%+13.16%+1.49%+8.40%+3,093.07%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-5.51%-11.11%+18.40%+12.76%-35.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.2105 of 5 stars
3.84.00.00.02.31.70.6
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.2627 of 5 stars
3.61.00.00.02.51.70.6
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
2.3479 of 5 stars
3.41.00.00.02.83.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
3.50
Strong Buy$9.00178.64% Upside
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.14
Buy$20.20237.23% Upside
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
0.00
N/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
2.83
Moderate Buy$40.00237.84% Upside

Current Analyst Ratings Breakdown

Latest JMAC, ATYR, ATAI, and RNAC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
7/2/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Aegis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/2/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $12.00
6/20/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.00
6/4/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$5.00
5/20/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/19/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00
5/13/2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$41.00 ➝ $40.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
$310K2,087.41N/AN/A$0.69 per share4.68
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$230K2,317.87N/AN/A$0.83 per share7.22
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
N/AN/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$38.91M7.90N/AN/A($0.27) per share-43.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$149.27M-$0.91N/AN/AN/AN/A-102.10%-77.55%8/12/2025 (Estimated)
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$64.02M-$0.810.00N/AN/AN/A-87.09%-64.77%8/12/2025 (Estimated)
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$77.42M-$52.830.00N/AN/AN/AN/A-7.01%8/6/2025 (Estimated)

Latest JMAC, ATYR, ATAI, and RNAC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025N/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.77N/AN/AN/A$0.77 millionN/A
8/12/2025Q2 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.13N/AN/AN/AN/AN/A
8/12/2025Q2 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18N/AN/AN/AN/AN/A
5/14/2025Q1 2025
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
-$0.19-$0.15+$0.04-$0.15N/A$1.56 million
5/8/2025Q1 2025
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 million
5/7/2025Q1 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.19-$0.17+$0.02-$0.17N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
N/AN/AN/AN/AN/A
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
N/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
0.08
4.07
4.07
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
0.01
7.79
7.79
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
N/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/A
12.34
12.34

Institutional Ownership

CompanyInstitutional Ownership
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
28.41%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
73.18%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
86.95%

Insider Ownership

CompanyInsider Ownership
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
26.80%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.70%
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
19.27%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
60.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
atai Life Sciences N.V. stock logo
ATAI
atai Life Sciences
80200.34 million146.65 millionOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5389.00 million85.71 millionOptionable
Maxpro Capital Acquisition Corp. stock logo
JMAC
Maxpro Capital Acquisition
2,02113.43 million10.84 millionNot Optionable
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
6425.95 million10.30 millionOptionable

Recent News About These Companies

Q2 Earnings Forecast for RNAC Issued By Wedbush
Brokers Set Expectations for RNAC Q2 Earnings
Cartesian Therapeutics management to meet with BTIG

New MarketBeat Followers Over Time

Media Sentiment Over Time

atai Life Sciences stock logo

atai Life Sciences NASDAQ:ATAI

$3.23 +0.44 (+15.77%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.32 +0.09 (+2.79%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$5.99 +0.20 (+3.45%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$6.16 +0.18 (+2.92%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Maxpro Capital Acquisition stock logo

Maxpro Capital Acquisition NASDAQ:JMAC

$6.21 -0.24 (-3.72%)
As of 07/18/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Cartesian Therapeutics stock logo

Cartesian Therapeutics NASDAQ:RNAC

$11.84 -0.69 (-5.51%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$12.15 +0.31 (+2.62%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.